Tourmaline Bio
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2002-01-01
- Employees
- 44
- Market Cap
- $428.2M
- Website
- http://www.tourmalinebio.com
- Introduction
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.
A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP
- Conditions
- Hs-CRPChronic Renal DiseasesHigh Sensitivity C-Reactive ProteinChronic Kidney DiseasesChronic Kidney InsufficiencyC-Reactive ProteinKidney Insufficiency, ChronichsCRPChronic Renal Insufficiency
- Interventions
- Drug: TOUR006 - 15 MGDrug: TOUR006 - 25 MGOther: PlaceboDrug: TOUR006 - 50 MG
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Tourmaline Bio, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT06362759
- Locations
- 🇺🇸
Site - 0124, Birmingham, Alabama, United States
🇺🇸Site - 0101, Birmingham, Alabama, United States
🇺🇸Site - 0135, Huntsville, Alabama, United States
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
- Conditions
- Thyroid Eye Disease
- Interventions
- Drug: TOUR006 - 20 MGOther: PlaceboDrug: TOUR006 - 50 MG
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Tourmaline Bio, Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT06088979
- Locations
- 🇺🇸
Bascom Palmer Eye Institute Site - 0115, Miami, Florida, United States
🇺🇸Cordova Research Institute - Site 0103, Miami, Florida, United States
🇺🇸Catalina Eye Care Site - 0121, Tucson, Arizona, United States
A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Biological: FCR001
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Talaris Therapeutics Inc.
- Registration Number
- NCT05098145
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation
- Conditions
- Transplanted Organ Rejection
- Interventions
- Biological: FCR001
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Talaris Therapeutics Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03995901
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)
- Conditions
- Metachromatic Leukodystrophy
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Talaris Therapeutics Inc.
- Registration Number
- NCT02084121
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)
- Conditions
- Renal Failure
- First Posted Date
- 2014-01-31
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Talaris Therapeutics Inc.
- Registration Number
- NCT02051673
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
Single Patient Expanded Access Protocol: Metabolic Boost
- Conditions
- Metachromatic Leukodystrophy
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Talaris Therapeutics Inc.
- Registration Number
- NCT02021266
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients
- Conditions
- Kidney Transplantation
- Interventions
- Biological: FCR001
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Talaris Therapeutics Inc.
- Registration Number
- NCT01649388
- Locations
- 🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸University of Minnesota Medical Center, Minneapolis, Minnesota, United States
Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies
- Conditions
- Complex and Transfusion-dependent HemoglobinopathiesAlpha-ThalassemiaAnemia, Sickle CellBeta-ThalassemiaThalassemiaDiamond-Blackfan AnemiaBone Marrow Failure Syndromes
- Interventions
- Biological: Enriched Hematopoetic Stem Cell Infusion
- First Posted Date
- 2011-08-18
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Talaris Therapeutics Inc.
- Registration Number
- NCT01419704
- Locations
- 🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders
- Conditions
- Metachromatic Leukodystrophy (MLD)Pelizaeus Merzbacher (PMD)Alpha-mannosidosisHunter Syndrome (MPS II)Sanfilippo Syndrome (MPS III)Krabbe Disease (Globoid Leukodystrophy)Sandhoff DiseaseTay Sachs DiseaseAdrenoleukodystrophy (ALD and AMN)Niemann-Pick Disease
- Interventions
- Biological: hematopoietic stem cell infusion
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Talaris Therapeutics Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT01372228
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States